Congenital Heart Disease– Pipeline Review, 2019

Congenital heart diseases are one of the most common types of birth diseases; the babies are born with. Congenital heart diseases refer to the defects in the structure of the heart. According to the American Heart Association, nine out of every 1,000 babies are born with congenital heart disease in the U.S. Common symptoms of congenital heart diseases include abnormal heart rhythm, cyanosis, edema, shortness of breath, chest pain, and others.

Current treatment of congenital heart diseases includes surgery and medication. Medications are prescribed to prevent the formation of clots and efficient functioning of the heart. Surgical treatment methods include the use of implantable heart devices such as implantable cardioverter defibrillators and pacemakers. Catheterization techniques, open-heart surgery, and heart transplantation are done for serious cases. 

According to the Centers for Disease Control and Prevention, congenital heart diseases affect nearly 40,000 babies per year in the U.S. Limited drugs and increasing prevalence of congenital heart diseases have surged the demand for a novel therapy for congenital heart diseases. Pharmaceutical companies and various research institutes have been focusing on developing new treatment options for congenital heart diseases. For instance; Actelion Pharmaceuticals Ltd. is conducting phase 3 clinical trials on Macitentan for the treatment of congenital heart disease.

At present, around 37% of the pipeline candidates for congenital heart disease are in phase 2 clinical stage. Majority of the studies are sponsored by academic research institutes.

Report Description

The report on ‘Congenital Heart Disease– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Congenital Heart Disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Congenital Heart Disease.

The report on ‘Congenital Heart Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Congenital Heart Disease


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Congenital Heart Disease


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary